A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia

Study Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia
Teva Identifier
TV48125-PN-20028
ClinicalTrials.gov Identifier
NCT03965091
Study Status
Terminated
Trial Condition(s)
Fibromyalgia
Interventions
Drug: Fremanezumab|Drug: Placebo
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
pain-icon

Key Participation Requirements

Gender
Female, Male
Age group
Adult, Older Adult
Age Range
18 Years to 75 Years
Trial Duration
July 31, 2019 - January 19, 2022
Phase
Phase 2

Study Type

Interventional